Literature DB >> 29425833

Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis.

Runting Yin1, Le Guo2, Jingya Gu3, Chunling Li3, Wei Zhang3.   

Abstract

Metastastic breast cancer, especially triple-negative (TN), is one of the most common causes of cancer related deaths in women. Recent years, tumor-associate vessel formation is considered as a more generally and effective target to patient with malignant cancer. Our previous studies indicated that miR-19b-1 controls the intrinsic angiogenic activity of human umbilical vein endothelial cells (HUVECs) in vitro. In this study, in silico analysis indicated VEZF1 that implicates in angiogenesis and triple-negative breast cancer progression might be the target of miR-19b-1. Further investigation showed that overexpressing miR-19b-1 in human triple-negative breast cancer cell line(MDA-MB-231) led to impaired angiogenic activity of HUVECs in vitro and in vivo. Additionally, miR-19b-1 upregulation inhibited the vessel imitation mediated by MDA-MB-231. Furthermore, enforced expression of miR-19b-1 in MDA-MB-231 has impact on HUVECs apoptosis and altered the mitochondrial membrane potential, which suggested the possible mechanism involved in interaction between breast cancer and endothelial cells. What's more, we found that miR-19b-1 stable overexpression in MDA-MB-231 caused tumor growth arresting entirely. Besides, our results suggested that miR-19b-1 could inhibit angiogenesis by possibly targeting VEGF receptor endocytosis signaling pathway. Taking together, our findings suggest an important role of miR-19b-1 in crosstalk between metastatic breast cancer and endothelial cells and provide us new insights for exploring miR-19b-1 and its multiple targets as promising therapeutic candidates to interfere breast cancer progression.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; TME; TN breast cancer; miR-19b-1

Mesh:

Substances:

Year:  2018        PMID: 29425833     DOI: 10.1016/j.biocel.2018.02.005

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  7 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  VEZF1, destabilized by STUB1, affects cellular growth and metastasis of hepatocellular carcinoma by transcriptionally regulating PAQR4.

Authors:  Xiaobao Shi; Pengfei Zhao; Gang Zhao
Journal:  Cancer Gene Ther       Date:  2022-10-14       Impact factor: 5.854

3.  Let-7d and miR-185 Impede Epithelial-Mesenchymal Transition by Downregulating Rab25 in Breast Cancer.

Authors:  Arman Shahabi; Behrooz Naghili; Khalil Ansarin; Maryam Montazeri; Mehdi Dadashpour; Nosratollah Zarghami
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

4.  Functional Linkage of RKIP to the Epithelial to Mesenchymal Transition and Autophagy during the Development of Prostate Cancer.

Authors:  Mahmoud Ahmed; Trang Huyen Lai; Sahib Zada; Jin Seok Hwang; Trang Minh Pham; Miyong Yun; Deok Ryong Kim
Journal:  Cancers (Basel)       Date:  2018-08-16       Impact factor: 6.639

Review 5.  MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer.

Authors:  Mohammad Mijanur Rahman; Andrew C Brane; Trygve O Tollefsbol
Journal:  Cells       Date:  2019-10-08       Impact factor: 6.600

6.  Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.

Authors:  Tatiana Kalinina; Vladislav Kononchuk; Efim Alekseenok; Darya Obukhova; Sergey Sidorov; Dmitry Strunkin; Lyudmila Gulyaeva
Journal:  Genes (Basel)       Date:  2021-04-16       Impact factor: 4.096

Review 7.  Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding the Anti-Angiogenesis Resistance Mechanisms.

Authors:  Wafaa S Ramadan; Dana M Zaher; Alaa M Altaie; Iman M Talaat; Adel Elmoselhi
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.